Pfizer expands potential in gene therapy field

In the latest sign that the major biopharma players are eagerly joining the big tech rush on the gene therapy market, Pfizer has snagged an option to buy a Paris-based biotech with a lead program a rare liver disease.

The pharma giant is paying $51 million to play, setting aside a stack of $636 million in milestone money if it chooses to go ahead with the buyout of Vivet Therapeutics on a near-term basis.